Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus

被引:319
作者
Komoroski, B. [1 ]
Vachharajani, N. [1 ]
Feng, Y. [1 ]
Li, L. [1 ]
Kornhauser, D. [1 ]
Pfister, M. [1 ]
机构
[1] Bristol Myers Squibb Co, Discovery Med & Clin Pharmacol, Res & Dev, Princeton, NJ USA
关键词
RENAL GLUCOSURIA; INSULIN; REABSORPTION; SECRETION; MUTATION;
D O I
10.1038/clpt.2008.250
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Dapagliflozin, administered to patients in once-daily oral doses, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that blocks the reabsorption of glucose from urine into the blood. This 14-day study randomized patients with type 2 diabetes mellitus (T2DM) to four treatment groups receiving daily oral doses of 5-, 25-, or 100-mg doses of dapagliflozin or placebo, in order to evaluate glucosuria and glycemic parameters. Significant reductions in fasting serum glucose (FSG) were observed on day 2 with 100 mg dapagliflozin (-9.3%, P < 0.001), and dose-dependent reductions were observed on day 13 with the 5- mg (-11.7%; P < 0.05), 25- mg (-13.3%; P < 0.05), and 100-mg (-21.8%; P < 0.0001) doses as compared with placebo. Significant improvements in oral glucose tolerance test (OGTT) were observed with all doses on days 2 and 13 (P < 0.001 as compared with placebo). On day 14, urine glucose values were 36.6, 70.1, and 69.9 g/day for the 5-, 25-, and 100-mg doses (as compared with no change for placebo), which were slightly lower than those on day 1. This was attributed to the decrease in filtered glucose load following improved glycemic control. Dapagliflozin produced dose-dependent increases in glucosuria and clinically meaningful changes in glycemic parameters in T2DM patients.
引用
收藏
页码:513 / 519
页数:7
相关论文
共 23 条
[1]   INSULIN THERAPY IN OBESE, NON-INSULIN-DEPENDENT DIABETES INDUCES IMPROVEMENTS IN INSULIN ACTION AND SECRETION THAT ARE MAINTAINED FOR 2 WEEKS AFTER INSULIN WITHDRAWAL [J].
ANDREWS, WJ ;
VASQUEZ, B ;
NAGULESPARAN, M ;
KLIMES, I ;
FOLEY, J ;
UNGER, R ;
REAVEN, GM .
DIABETES, 1984, 33 (07) :634-642
[2]   Familial renal glucosuria:: SLC5A2 mutation analysis and evidence of salt-wasting [J].
Calado, J ;
Loeffler, J ;
Sakallioglu, O ;
Gok, F ;
Lhotta, K ;
Barata, J ;
Rueff, J .
KIDNEY INTERNATIONAL, 2006, 69 (05) :852-855
[3]  
Chen J, 2008, DIABETES, V57, pA682
[4]  
FENG Y, 2008, CLIN PHARM THER S1, V83, pS72
[5]   A novel SGLT2 mutation in a patient with autosomal recessive renal glucosuria [J].
Francis, J ;
Zhang, JH ;
Farhi, A ;
Carey, H ;
Geller, DS .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2004, 19 (11) :2893-2895
[6]  
GIBB D, 1995, NEW ZEAL MED J, V108, P252
[7]   Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats [J].
Han, Songping ;
Hagan, Deborah L. ;
Taylor, Joseph R. ;
Xin, Li ;
Meng, Wei ;
Biller, Scott A. ;
Wetterau, John R. ;
Washburn, William N. ;
Whaley, Jean M. .
DIABETES, 2008, 57 (06) :1723-1729
[8]   Sodium glucose co-transporter 2 (SGLT2) inhibitors as potential antidiabetic agents [J].
Handlon, AL .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2005, 15 (11) :1531-1540
[9]   Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level [J].
Katsuno, Kenji ;
Fujimori, Yoshikazu ;
Takemura, Yukiko ;
Hiratochi, Masahiro ;
Itoh, Fumiaki ;
Komatsu, Yoshimitsu ;
Fujikura, Hideki ;
Isaji, Masayuki .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2007, 320 (01) :323-330
[10]  
Komoroski B, 2007, DIABETES, V56, pA49